



Chlorate Specifically Targets Oxidant-Starved, Antibiotic-Tolerant Populations of *Pseudomonas aeruginosa* Biofilms

Melanie A. Spero,^a  Dianne K. Newman^{a,b}

^aDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, California, USA

^bDivision of Geological and Planetary Sciences, California Institute of Technology, Pasadena, California, USA

ABSTRACT Nitrate respiration is a widespread mode of anaerobic energy generation used by many bacterial pathogens, and the respiratory nitrate reductase, Nar, has long been known to reduce chlorate to the toxic oxidizing agent chlorite. Here, we demonstrate the antibacterial activity of chlorate against *Pseudomonas aeruginosa*, a representative pathogen that can inhabit hypoxic or anoxic host microenvironments during infection. Aerobically grown *P. aeruginosa* cells are tobramycin sensitive but chlorate tolerant. In the absence of oxygen or an alternative electron acceptor, cells are tobramycin tolerant but chlorate sensitive via Nar-dependent reduction. The fact that chlorite, the product of chlorate reduction, is not detected in culture supernatants suggests that it may react rapidly and be retained intracellularly. Tobramycin and chlorate target distinct populations within metabolically stratified aggregate biofilms; tobramycin kills cells on the oxic periphery, whereas chlorate kills hypoxic and anoxic cells in the interior. In a matrix populated by multiple aggregates, tobramycin-mediated death of surface aggregates enables deeper oxygen penetration into the matrix, benefiting select aggregate populations by increasing survival and removing chlorate sensitivity. Finally, *lasR* mutants, which commonly arise in *P. aeruginosa* infections and are known to withstand conventional antibiotic treatment, are hypersensitive to chlorate. A *lasR* mutant shows a propensity to respire nitrate and reduce chlorate more rapidly than the wild type does, consistent with its heightened chlorate sensitivity. These findings illustrate chlorate's potential to selectively target oxidant-starved pathogens, including physiological states and genotypes of *P. aeruginosa* that represent antibiotic-tolerant populations during infections.

IMPORTANCE The anaerobic growth and survival of bacteria are often correlated with physiological tolerance to conventional antibiotics, motivating the development of novel strategies targeting pathogens in anoxic environments. A key challenge is to identify drug targets that are specific to this metabolic state. Chlorate is a nontoxic compound that can be reduced to toxic chlorite by a widespread enzyme of anaerobic metabolism. We tested the antibacterial properties of chlorate against *Pseudomonas aeruginosa*, a pathogen that can inhabit hypoxic or anoxic microenvironments, including those that arise in human infection. Chlorate and the antibiotic tobramycin kill distinct metabolic populations in *P. aeruginosa* biofilms, where chlorate targets anaerobic cells that tolerate tobramycin. Chlorate is particularly effective against *P. aeruginosa lasR* mutants, which are frequently isolated from human infections and more resistant to some antibiotics. This work suggests that chlorate may hold potential as an anaerobic prodrug.

KEYWORDS Nar, *Pseudomonas aeruginosa*, antibiotic tolerance, biofilms, chlorate, nitrate reduction, prodrug

Nitrate respiration is a widespread mode of anaerobic energy generation that bacterial pathogens use to adapt to anoxic host environments (1, 2). Not only is nitrate one of the most energetically favorable electron acceptors used in anaerobic

Received 26 June 2018 Accepted 22 August 2018 Published 25 September 2018

Citation Spero MA, Newman DK. 2018. Chlorate specifically targets oxidant-starved, antibiotic-tolerant populations of *Pseudomonas aeruginosa* biofilms. mBio 9:e01400-18. <https://doi.org/10.1128/mBio.01400-18>.

Editor Susan Gottesman, National Cancer Institute

Copyright © 2018 Spero and Newman. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Dianne K. Newman, dkn@caltech.edu.

respiration, it is available at various sites in the human body, deriving from reactions between nitric oxide and superoxide produced during the host inflammatory response (3). In the gut, enteric pathogens respire host-derived nitrate to outcompete the obligate anaerobes that typically dominate this environment, contributing to inflammatory bowel disease (4–6). In *Mycobacterium tuberculosis* and its relatives, there is evidence that the respiration of macrophage-derived nitrate is required for growth, virulence, and persistence (7–9). Pathogenic species of *Staphylococcus*, *Burkholderia*, and *Brucella* also employ nitrate respiration to adapt to host-like environments, although the *in vivo* role of this physiology is not fully understood (10–14). The prevalence of nitrate respiration in bacterial pathogenesis marks this mode of energy generation as a potential therapeutic target for disparate infections.

Included among pathogens known to respire nitrate is *Pseudomonas aeruginosa*, which causes a range of acute and chronic infections (15). *P. aeruginosa* infections contribute to chronic wounds, ventilator-associated pneumonia, and the morbidity and mortality of patients with cystic fibrosis (CF), in whom these infections persist despite aggressive antibiotic treatment (16–18). Nitrate respiration likely supports *P. aeruginosa* growth and survival in the host, because microenvironments within chronic wounds and the sputum in CF patient lungs contain appreciable anoxic zones and nitrate concentrations (19–23). Although *P. aeruginosa* has three nitrate reductases (Nar, Nap, and Nas) (24), only the Nar enzyme couples nitrate reduction to proton translocation and is required for anaerobic growth (25). Transcription of the *nar* operon is activated under hypoxic/anoxic conditions and further stimulated by the presence of nitrate (25), so it is unsurprising that *nar* gene expression (26, 27) and the metabolic products of nitrate respiration have been detected in CF patient sputum (21, 28) and that Nar antibodies have been detected in the sera of CF patients (29).

One reason that *P. aeruginosa* infections might persist for decades despite antibiotic use is that oxidant-starved pathogen populations can be physiologically tolerant of antibiotics. Low-oxygen tensions in host environments limit the growth rates of pathogens (21, 30, 31), and slowly growing *P. aeruginosa* cells show increased physiological tolerance toward some classes of antibiotics (32, 33). Diverse reasons can explain this tolerance: (i) conventional drug targets are inappropriate (e.g., cell division inhibitors harm only cells that are actively dividing and may not harm slowly growing cells) (34), (ii) common antibiotics cannot be taken up (e.g., aminoglycosides require active transport, but if the cell membrane is insufficiently charged to allow these transporters to work, they will not enter the cell [35–37]), and (iii) target pathogens are physically sequestered and thereby less accessible to the immune system or conventional drugs (38). Many pathogens, including *P. aeruginosa*, also grow as aggregate biofilms in host sputum and tissue or on medical implants or catheters (39, 40). Biofilms are physiologically heterogeneous; exterior cells with access to oxygen respire aerobically, whereas interior cells experience hypoxia or anoxia, display markers of slow growth, and are physiologically tolerant of antibiotics used to treat *P. aeruginosa* infections, such as the aminoglycoside tobramycin (41–43). *P. aeruginosa* cells require a threshold membrane potential for aminoglycoside uptake, and antibiotic-tolerant populations can be sensitized via the addition of an electron acceptor or a carbon source that stimulates metabolic activity (44, 45).

Genetic changes accumulate in *P. aeruginosa* over the course of infection, and strains with inactivating mutations in *lasR* are known to arise rapidly in some host environments (46, 47). *lasR* mutants have been isolated from patients with bacteremia, pneumonia, chronic wounds, and CF (48–50). The prominence of *lasR* mutants has been best documented in CF studies, where they are among the most frequently isolated mutants from CF patients (49) and their presence is associated with worse lung function (46). *lasR* mutants are also more resistant to antibiotics commonly used to treat *P. aeruginosa* infections (51, 52). *lasR* encodes a quorum-sensing regulator, so the loss of this gene has pleiotropic effects (52), but intriguingly, one phenotypic trait of *lasR* mutants is their decreased rates of oxygen respiration and increased rates of Nar-dependent nitrate respiration (51). Selection for mutants that, besides having other




FIG 1 Chlorate kills oxidant-starved *P. aeruginosa* cells displaying physiological tolerance to tobramycin. Viable-cell plate counts from *P. aeruginosa* cultures that were incubated for 4 h without (untreated) or with 40 $\mu\text{g/ml}$ tobramycin, 10 mM chlorate, 40 $\mu\text{g/ml}$ tobramycin plus 10 mM chlorate, or 10 mM chlorite. Cultures were incubated with these compounds under oxic conditions (black), anoxic conditions with 40 mM nitrate (dark gray), or anoxic conditions without nitrate (light gray). Data show the means of results of 9 biological replicates from 3 independent experiments, and error bars indicate standard errors.

traits, are metabolically rewired toward nitrate respiration supports the hypothesis that this mode of anaerobic energy generation plays an important role for *P. aeruginosa* *in vivo*. Because oxidant-starved and genetic (e.g., *lasR* mutant) populations are more antibiotic tolerant and synthesize Nar, we hypothesized that targeting nitrate respiration might provide a new approach for treating *P. aeruginosa* infections.

Chlorate has long been known to serve as a substrate for Nar. Since the 1960s, Nar activity has been distinguished from other nitrate reductases, such as Nap, by its ability to also reduce chlorate to chlorite (53, 54). While chlorate is a relatively stable, nontoxic compound, chlorite is a toxic, reactive oxidizing agent (55, 56). Thus, chlorate is expected to be nontoxic to cells lacking Nar (e.g., mammalian cells) and specifically kill Nar-containing bacterial cells via cytoplasmic chlorite production. Consistent with this logic, chlorate has been successfully used to control pathogens in studies of agricultural systems, where livestock that ingested chlorate had lowered intestinal and fecal enteric-pathogen counts (57). Importantly, the treated animals showed no measurable health effects with very high quantities of ingested chlorate (e.g., 250 mg kg^{-1} of body weight per day [58]), including in one study in which serum chlorate concentrations reached 1 mM in sheep (59). Reports also indicate that chlorate shows low toxicity in humans, with an estimated lethal oral dose of 20 to 35 g (60, 61).

Considering the central role that Nar-mediated nitrate respiration likely plays in the survival of bacterial pathogens in diverse host environments, we reasoned that chlorate treatment might offer an effective means of targeting anaerobic populations, such as those within the oxidant-limited interiors of biofilms. Here, we begin to test this hypothesis by exploring the antibacterial activity of chlorate against different physiological states of *P. aeruginosa*.

RESULTS

Chlorate kills *P. aeruginosa* cultures displaying physiological tobramycin tolerance. Because tobramycin is most effective at killing aerobically growing *P. aeruginosa* cells (42, 43), whereas chlorate is predicted to target cells containing Nar (25), we first determined whether these compounds were effective under different conditions of oxidant exposure. High-density *P. aeruginosa* cultures ($\sim 10^9$ CFU ml^{-1}) were incubated with and without drugs under oxic conditions, anoxic conditions with 40 mM nitrate, or anoxic conditions without nitrate (no terminal electron acceptor) for 4 h, after which viability was determined (Fig. 1). As predicted, oxic cultures are sensitive to tobramycin. Anoxic cultures are sensitive to tobramycin when supplied with nitrate but tolerant in the absence of an electron acceptor. Conversely, chlorate does not kill oxic cultures or




FIG 2 Chlorate consumption is correlated with cell death during oxidant starvation. *P. aeruginosa* cultures were incubated without (untreated) or with 1 mM chlorate (chlorate treated) under oxic conditions (A) or under anoxic conditions with 40 mM nitrate (B). Cultures were monitored for 72 h to determine viable-cell counts (top) and chlorate and nitrate concentrations (bottom) over time. The dashed line in panel B shows the time when nitrate concentrations approximate zero in chlorate-treated cultures. Data show the means of results from 3 biological replicates, and error bars indicate standard errors. In some cases, error bars are smaller than the size of the symbols.

anoxic cultures supplied with nitrate, while anoxic cultures lacking nitrate are sensitive to chlorate. These findings are consistent with those of prior studies demonstrating that cells require a minimum membrane potential for tobramycin uptake and efficacy (35, 36), which can be established by oxygen or nitrate respiration.

Although anoxic cultures supplied with nitrate utilize Nar, these cells are chlorate tolerant (Fig. 1). However, nitrate concentrations in these experiments were 4-fold higher than chlorate concentrations. When nitrate is provided to anoxic cultures at low concentrations that approximate those found in CF patient sputum or chronic wounds (400 μ M nitrate) (19, 23), tobramycin and chlorate lethality is indistinguishable from that in cultures lacking nitrate (see Fig. S1 in the supplemental material). We attribute this to the fact that under these conditions, 400 μ M nitrate is completely consumed in a short time period (see Fig. 2B). Combined chlorate and tobramycin treatment under oxic conditions or anoxic conditions plus nitrate results in killing similar to that of tobramycin treatment alone, but combined treatment yields greater death under anoxic conditions (Fig. 1) (0.9 \log_{10} CFU ml⁻¹ more death with the combined treatment than with chlorate treatment; *t* test, $P < 0.0001$). Lastly, we looked at sensitivity to chlorite, the predicted product of Nar-mediated chlorate reduction. Anoxic cultures are much more sensitive to chlorite than oxic cultures (Fig. 1). The mechanism of chlorite toxicity is not fully understood, although it and other reactive chlorine species are known to oxidize amino acids (62, 63), inducing cell death via protein aggregation (64). Cells with sufficient access to a respiratory oxidant may be better equipped to handle this stress because they have more energy for repair (65, 66).

Chlorate toxicity requires chlorate consumption and is protected by respiration. To determine whether chlorate reduction is linked to cell death, we monitored cell viability and chlorate concentrations in oxic cultures over 72 h. Under these conditions, chlorate concentrations are stable, and likewise, there is no chlorate-associated cell

death (Fig. 2A). In anoxic cultures supplemented with 40 mM nitrate, nitrate is consumed quickly and undetectable within 8 h (Fig. 2B). During nitrate consumption, chlorate is consumed at a seemingly constant rate, although much more slowly than nitrate consumption. Chlorate-associated cell death does not occur until nitrate is consumed (dashed line in Fig. 2B). This result suggests that anaerobic respiration may protect cells from chlorate toxicity, perhaps by supplying energy required for chlorite detoxification or repair.

Changes in chlorate and nitrate concentrations can be attributed to cell activity because concentrations of these compounds are stable in abiotic controls (Fig. S2). Further, assuming a 1:1 stoichiometry of chlorate-chlorite converted by Nar, chlorite concentrations exceed our experimental detection limit (1 μ M) at the observed rates of chlorate consumption. However, we did not detect chlorite in any of our experiments, potentially because chlorite reacts with intracellular components before measurable concentrations can accumulate. Similarly, other reactive chlorine species are known to react quickly with biomolecules (63).

Nar genes are required for chlorate consumption and toxicity. Having found a correlation between chlorate consumption during oxidant starvation and cell death, we tested whether Nar is required for chlorate consumption and toxicity. In these experiments, we used the wild type (WT) and a *narG* transposon mutant and complemented these strains with *narGHJI* (encoding Nar structural subunits and assembly proteins) carried by an arabinose-inducible vector or with an empty vector. Because *narG* mutants cannot grow anaerobically, all strains were grown aerobically, washed and resuspended in fresh medium containing or lacking chlorate, and moved to an anaerobic chamber to adapt to anoxia. Viable-cell plate counts were determined after a 72-h incubation. While oxic WT cultures are not sensitive to chlorate (Fig. 1), anoxia-adapted cultures show a 5-log decrease in viable-cell counts compared to untreated cultures (Fig. 3A). The *narG* mutant, however, is resistant to chlorate; complementation with the *narGHJI* genes restores chlorate sensitivity to the *narG* mutant, while the empty vector has no effect. Likewise, chlorate concentrations are stable in *narG* mutant cultures over the course of the experiment, while chlorate concentrations decrease in WT and *narG* mutant-complemented cultures (Fig. 3B). This demonstrates that Nar is necessary and sufficient for chlorate reduction and its associated cell death.

Because *P. aeruginosa* can also reduce nitrate with the periplasmic nitrate reductase Nap (24), we tested whether Nap also contributes to chlorate sensitivity. *napA* insertion mutant strains consume 9% less chlorate than WT strains (with and without empty vector strains; *t* test, $P = 0.02$) and have a 3-fold-higher percentage of survival (with and without empty vector strains; *t* test, $P = 0.004$). This suggests that periplasmic Nap may play a small role in chlorate reduction, which differs from findings of a prior report stating that this enzyme is incapable of chlorate reduction (53). When *nap* genes are overexpressed in a *narG* mutant background, 15% of the chlorate is consumed. Surprisingly, this is associated with very little cell death (78% survival). Indeed, all strains overexpressing *nap* genes consume more chlorate yet survive better than their empty-vector counterparts (*t* test, all $P < 0.02$). Similarly, the WT strain overexpressing *nar* genes consumes more chlorate than its empty-vector counterpart (*t* test, $P < 0.0001$), yet survives better (*t* test, $P = 0.002$) (Fig. 3A). The relationship between chlorate reduction and death, thus, appears to be nuanced and may be influenced both by the cellular location of the chlorate reduction machinery and by the chlorate reduction rate.

The Δ lasR strain has increased rates of nitrate respiration and increased chlorate sensitivity. Because *P. aeruginosa lasR* mutants have increased rates of Nar-mediated nitrate respiration under oxic and hypoxic conditions (51), we hypothesized that such mutants might be particularly chlorate sensitive. To test this, we compared the levels of growth and nitrate consumption of WT and Δ lasR strains under different conditions. The WT and the Δ lasR mutant grow similarly under oxic conditions (Fig. 4A), but upon addition of 40 mM nitrate, the Δ lasR mutant grows more quickly than the WT during late exponential/early stationary phase, though both cultures




FIG 3 *nar* genes are required for chlorate reduction and sensitivity. Strains were grown aerobically, resuspended in fresh medium containing or lacking 1 mM chlorate, and incubated in an anaerobic glove box for 72 h. (A) The percent survival was calculated for each strain as the viable-cell counts in chlorate-treated cultures divided by the mean viable-cell count in untreated cultures at the end of the incubation, multiplied by 100. (B) The percentage of chlorate remaining was calculated for each strain as the concentration of chlorate in each culture at the end of the incubation divided by the initial concentration in the medium, multiplied by 100. Strains with pEV, *pnar*, and *pnap*, indicate strains that contain an empty vector, a vector with *narGHJI*, and a vector with *napEFDABC*, respectively. Three biological replicates of both treated and untreated cultures were used in this experiment, and error bars indicate standard errors.

ultimately reach the same maximum cell density (Fig. 4B). This increased growth rate correlates with increased nitrate consumption by the $\Delta lasR$ mutant, which consumes all supplemented nitrate, whereas the WT consumes only 12% over 36 h (Fig. 4B). During anaerobic growth with 40 mM nitrate, the $\Delta lasR$ mutant also consumes nitrate more quickly than the WT and does so to completion, whereas the WT consumes only 50% over 24 h (Fig. 4C). Here, rapid and complete nitrate consumption allows anoxic $\Delta lasR$ cultures to grow faster and achieve higher cell densities than those of the WT. Finally, when incubated under anoxic conditions with chlorate, the $\Delta lasR$ mutant consumes chlorate more quickly than the WT, which correlates with increased rates of chlorate-associated cell death (Fig. 4D). Although similar amounts of chlorate were ultimately consumed by both strains, viable-cell counts were 100-fold lower in $\Delta lasR$ cultures at the end of the experiment, demonstrating that *lasR* mutants are particularly susceptible to anoxic chlorate treatment. In control experiments, we found that a $\Delta lasR \Delta narGHJI$ strain is chlorate tolerant (Fig. S3) and shows WT levels of nitrate utilization (Fig. S4), demonstrating that chlorate sensitivity in the *lasR* strain is *nar* dependent.

Chlorate and tobramycin target distinct populations in aggregate biofilms. To assess whether our findings in planktonic cultures might apply to a biofilm mode of growth that approximates that found *in vivo* (40), we used an agar block biofilm assay




FIG 4 The $\Delta lasR$ mutant has increased rates of nitrate respiration and chlorate consumption and is more sensitive to chlorate. Cell density (OD_{500} , filled circles) and nitrate concentrations (open circles) were monitored in the WT and $\Delta lasR$ mutant cultures growing under oxic conditions (A), oxic conditions with 40 mM nitrate (B), and anoxic conditions with 40 mM nitrate (C). (D) The WT and $\Delta lasR$ cultures were incubated without (squares) or with (filled circles) 1 mM chlorate under anoxic conditions for 72 h, over which time viable-cell counts (solid lines) and chlorate concentrations (dashed lines) were monitored. Data from all experiments show the means of results from three biological replicates, and error bars indicate standard errors.

(ABBA) to study aggregate biofilms. In the ABBA system, an overnight culture is diluted into 0.5% molten agar medium, allowed to solidify, and incubated overnight at 37°C. Agar-suspended cells grow as aggregates, which develop into metabolically distinct populations at different spatial scales. Over time, aggregates near the top of the agar grow more quickly than aggregates deeper in the agar because they consume oxygen that is enriched at the surface, which decreases oxygen availability to deeper aggregates (67, 68) (Fig. 5A). Oxygen gradients can also develop within large aggregates, where cells on the exterior scavenge oxygen before those on the interior can access it (69). We predicted that biofilm cells with access to oxygen are tobramycin sensitive and chlorate tolerant but that cells that are oxygen starved are tobramycin tolerant and chlorate sensitive.

P. aeruginosa aggregates were grown overnight in Luria-Bertani medium (LB) agar supplemented with 5 mM nitrate, after which they were treated for 6 h by pipetting LB with or without tobramycin, chlorate, or both compounds on top of the agar blocks. Following treatment, aggregates were stained with SYTO 9 and propidium iodide (PI) and imaged via confocal microscopy (Fig. 5B and Movie S1 to S4). SYTO 9 is membrane permeable and stains all cells, whereas PI is membrane impermeable and, thus, thought to enter nonviable cells with damaged membranes where it displaces SYTO 9 (70). Though PI can stain viable cells that grow slowly and have a weak membrane potential (71), because a relatively small proportion of cells stain with PI in untreated samples (Fig. 5C), we interpret PI- or SYTO 9-stained cells as dead or alive in response to drug treatment, respectively. We found that cells in surface aggregates are killed by tobramycin, whereas those at depth are tobramycin tolerant (Fig. 5B). The pattern corresponds to the expected profile of oxygen availability (67). Cells in middepth aggregates display graded sensitivity at the individual aggregate scale, with cells on the exterior being killed and cells on the interior staying alive. Chlorate targets the opposite population: surface aggregates and the exterior of middepth aggregates are chlorate tolerant, whereas aggregates at depth and the interior of middepth aggregates are killed (Fig. 5B). These findings are consistent with those of our planktonic studies (Fig. 1), where cells with or without access to oxygen were found to be killed by tobramycin or chlorate, respectively.

Drug treatment alters oxygen gradients and drug sensitivity. Given that tobramycin and chlorate can target and kill distinct, complementary populations within metabolically stratified biofilms, we anticipated that combined tobramycin and chlorate treatment might compromise all cells within aggregate populations, but paradoxically, this proved not to be the case (Fig. 5B). In combined-treatment samples, aggregates at the surface were killed by tobramycin and aggregates at depth were killed by chlorate, but middepth aggregates stained similarly to tobramycin-only-treated samples (exterior killed, interior alive). Quantifying these ABBA live/dead profiles, we find that the combined treatment profile aligns with the tobramycin-only profile for the first 180 μm but that the depths where chlorate kills shifts: the depth at which 50% of the population is killed by chlorate is $162 \pm 14 \mu\text{m}$ (mean \pm standard error of the mean [SEM]) deeper in combined-treatment samples than in chlorate-only-treated samples (dashed arrow in Fig. 5C). We speculated that this shift might reflect changes in oxygen availability due to changes in cellular consumption rates, which might explain why combined treatment did not eradicate all cells.

To test this hypothesis, we measured oxygen profiles in ABBA samples (Fig. 6). In untreated samples, oxygen concentrations decrease until anoxia occurs at a depth of about 350 μm . However, tobramycin-treated samples never become anoxic; oxygen concentrations remain at around 50% of atmospheric values at even the greatest depths. This observation supports our hypothesis that the tobramycin-mediated death of surface and exterior cells allows for increased oxygen penetration, leading some populations in combined-treatment samples to shift from a chlorate-sensitive to a -tolerant state (depths of 120 to 220 μm) (Fig. 5C). Increased oxygen penetration also correlates with increased survival in tobramycin-only-treated samples compared to that




FIG 5 Tobramycin and chlorate target distinct populations in aggregate biofilms. (A) Cartoon of the agar block biofilm assay (ABBA), where cells suspended in agar medium grow as aggregate biofilms. At early incubations, aggregates are uniform in size, but oxygen gradients develop over time, both within the aggregate population and within individual aggregates, leading to a metabolically heterogeneous population. After 12 h of growth, aggregates are incubated with drugs for 6 h before they are stained and imaged via confocal microscopy. (B) Representative images of untreated aggregates and those treated with 40 μ g/ml tobramycin, 10 mM chlorate, or 40 μ g/ml tobramycin plus 10 mM chlorate (combined) are shown at three depths, where cells are stained with SYTO 9 (cyan; live) and propidium iodide (red; dead). The scale bar is 50 μ m for all images. (C) Confocal images were used to generate a sensitivity profile for each treatment condition, where the proportion of dead cells (propidium iodide intensity divided by the sum of the propidium iodide and SYTO 9 intensities) was determined at each depth. The dashed arrow highlights a shift in the depth, where 50% of cells are killed by chlorate in chlorate-only samples and compared to combined-treatment samples. Data show the means from 6 independent experiments, and error bars indicate standard errors.




FIG 6 Oxygen profiles in treated aggregate biofilm populations. Oxygen profiles of *P. aeruginosa* aggregate biofilms after a 6-h incubation without a treatment (black) or with 40 $\mu\text{g}/\text{ml}$ tobramycin (red), 10 mM chlorate (blue), or 40 $\mu\text{g}/\text{ml}$ tobramycin plus 10 mM chlorate (combined; purple). The yellow region highlights measurements taken above the surface of the agar, and the dashed black line shows oxygen profiles from uninoculated agar samples. Data show the means from 3 independent experiments, and colored regions indicate standard errors.

in untreated samples at depths of $>200\ \mu\text{m}$ (Fig. 5C). Oxygen consumption rates for equivalent SYTO-9-stained cells are lower in tobramycin-only-treated ($0.27\ \mu\text{M}/\mu\text{m}$) than in untreated ($0.50\ \mu\text{M}/\mu\text{m}$) samples at depths of 150 to 200 μm (Fig. 6), which may explain why tobramycin-treated cells remain viable at these depths. In chlorate-treated samples, oxygen concentrations decrease until about 200 μm but remain greater than zero (Fig. 6). This is consistent with our finding that most cells at depths of $>200\ \mu\text{m}$ are dead in chlorate-treated samples (Fig. 5C). As was expected, the combined-treatment samples are relatively oxygen replete (Fig. 6), presumably because few cells survive to respire oxygen.

Though we expected deep aggregates in tobramycin-treated samples to die over prolonged exposure or that sequential treatment with chlorate and then tobramycin (or vice versa) would kill all cells given enough time, we were unable to perform these experiments because the ABBA system is not amenable to incubations greater than a day (i.e., a large proportion of cells in the untreated controls stain with PI after ~ 20 h of incubation). Such experiments require a different experimental setup and are priorities for future work.

DISCUSSION

Nar-mediated nitrate respiration is commonly used by bacterial pathogens to adapt to hypoxic/anoxic host environments, marking Nar as a potential therapeutic physiological target for treating oxidant-limited infections. While it has long been known that Nar-mediated chlorate reduction is toxic to bacteria (72, 73), this is the first study to explore chlorate as a prodrug against antibiotic-tolerant pathogens. We show that Nar-mediated chlorate reduction in the absence of an electron acceptor kills *P. aeruginosa* cells that tolerate the aminoglycoside tobramycin. Within metabolically stratified aggregate biofilms, chlorate and tobramycin kill distinct populations, targeting cells in the hypoxic/anoxic and oxic zones, respectively. Tobramycin treatment perturbs the biofilm microenvironment by increasing oxygen penetration, which increases survival and removes chlorate sensitivity for certain members of the population. These findings demonstrate chlorate's potential therapeutic value and provide insight into how the physiological adaptation of pathogens plays a central role in drug efficacy.

We used *P. aeruginosa* in this study as a representative facultative anaerobe to begin to explore chlorate's potential as a prodrug. We were able to leverage knowledge from prior work regarding how *P. aeruginosa* adapts to host environments to inform our

experimental design. Given that *lasR* mutants are frequently isolated from *P. aeruginosa*-infected patients (48–50), they are more resistant to antibiotics commonly used to treat such infections (51, 52), and they have a propensity for Nar-mediated nitrate respiration (51), we explored the use of chlorate for killing this recalcitrant genetic population (46, 49, 51). Our finding that chlorate is more effective at killing the *lasR* mutant than the WT suggests that it may be particularly well suited to combat this clinically relevant mutant. The presence of *lasR* mutants in chronic wounds, blood infections, and the lungs of CF and pneumonia patients (46, 48, 50) suggests that this adaptation benefits *P. aeruginosa* in many host environments. However, because the primary mechanism of chlorate resistance in *P. aeruginosa* is a Nar-inactivating mutation (74), adaptation to the drug might severely compromise pathogen fitness *in vivo* (3).

Antibiotic treatment failure is often not attributable to genetic resistance, since patient isolates often show *in vitro* sensitivity to the administered antibiotic (75). Rather, oxidant-starved pathogen populations, such as those found in biofilms, may play a critical role in antibiotic tolerance and treatment failure (43). A number of strategies, including treatments that disrupt the proton motive force or cell membrane (76), reactivate cell metabolism (77), or activate a destructive pathway (78), are being explored for targeting this metabolic state. Colistin is known to kill oxidant-starved *P. aeruginosa* cells (41); however, while inhaled colistin therapy is widely used to treat chronic CF patient lung infections, whether its chronic use benefits patients is unclear (79). Azithromycin is also known to kill oxidant-starved *P. aeruginosa* cells (80), and while its use is associated with positive outcomes for CF patients, its chronic use has been associated with multidrug-resistant nontuberculosis mycobacterial infections (79, 81). In the case of CF, chronic tobramycin treatment remains the standard of care for patients with persistent *P. aeruginosa* infections (79), despite its inability to eradicate anaerobic populations. Thus, the potential for chlorate to kill oxidant-limited pathogens that tolerate tobramycin is worth exploring.

Given that many facultative anaerobic pathogens carry *nar* (1) and anoxia alone stimulates its expression in many of these organisms (25, 82, 83), chlorate might have broad potential application. One attractive aspect of chlorate is that, unlike antibiotics that are designed to inhibit an essential process (84), chlorate coopts the activity of its target to produce a toxic by-product. Thus, even though pathogens may employ other energetic schemes during anaerobic growth and survival (85, 86), chlorate-susceptible pathogens need only synthesize Nar rather than rely on it for survival. Such “Trojan horse” strategies have been explored in other contexts for bacteria and other pathogens (87, 88). Because Nar catalyzes the majority of chlorate reduction and is oriented toward the cytoplasm, we might anticipate that chlorate reduction does not harm neighboring cells lacking Nar (e.g., mammalian cells). Consistent with this prediction, chlorite did not accumulate in our planktonic cultures, nor did we find evidence that chlorate reduction in the anoxic zone of our biofilm populations harmed those in the oxic zone. However, it is possible that a toxic by-product other than chlorite is produced or released by chlorate-reducing cells that we did not detect. Going forward, it will be important to determine the mechanism of chlorate toxicity and which chlorine reduction products are involved, the extent to which chlorate-mediated killing is specific to target cells, the effective *in vivo* chlorate concentrations, and whether our *in vitro* results translate into positive outcomes in *in vivo* models.

Lastly, our results show that drug treatment can perturb the microenvironment around pathogens in such a way as to modulate their susceptibility to other drugs. Oxygen availability drives *P. aeruginosa* sensitivity to chlorate, tobramycin, and other antibiotics (32), so finding that tobramycin treatment itself increases oxygen availability to other members of the biofilm population is striking. When tobramycin treatment kills aerobically respiring populations on the biofilm exterior, it benefits cells in hitherto-hypoxic regions by increasing their access to oxygen, which in turn renders them, at least temporarily, tolerant to both tobramycin and chlorate. Ultimately, a direct examination of the energetic states that exist within a biofilm population, how they change

over time, and how they respond to drug perturbations will be necessary to understand and effectively respond to physiological antibiotic tolerance.

MATERIALS AND METHODS

Bacterial strains and growth conditions. Strains used in this study include *P. aeruginosa* PA14 (wild type [WT]), isogenic *narG* and *napA* transposon insertion mutants (25), and an isogenic, in-frame, markerless *lasR* deletion mutant (65). Strains that were constructed for this work are described below. All experiments used Luria-Bertani medium (LB; Difco) as a growth medium, supplemented with KNO₃ as specified. Aerobic liquid cultures were incubated at 37°C with shaking at 250 rpm. Anaerobic work was conducted in an anaerobic glove box with a 95% N₂-5% H₂ atmosphere, and anaerobic cultures were incubated at 33°C.

Bacterial-survival assays and viability measurements. In aerobic-survival endpoint assays, overnight aerobic cultures were pelleted, washed twice with and resuspended in LB, and added to a 96-well microtiter plate at high cell density (optical density at 500 nm [OD₅₀₀] ~ 3). Wells also contained sodium chlorate (final concentration, 10 mM), sodium chlorite (final concentration, 10 mM), tobramycin (final concentration, 40 µg ml⁻¹), or an equal volume (20 µl) of dH₂O in untreated-control wells (200-µl total volume per well). Ninety-six-well plates were incubated at 37°C with shaking at 250 rpm for 4 h before viable cells on plates were counted. Anaerobic-survival endpoint assays were performed as described above, except that overnight cultures were grown anaerobically at 33°C in LB with 40 mM KNO₃, cells were washed and resuspended in either LB or LB with 40 mM KNO₃ under anaerobic conditions, and 96-well plates were incubated anaerobically at 33°C for 4 h and then removed from the glove box so that cultures could be serially diluted for viable-cell plate counts.

Aerobic- and anaerobic-survival assays were also conducted over the course of 72 h. The experimental setup was the same as described above, except that culture volumes were 5 ml (in capped tubes), cultures were treated with 1 mM sodium chlorate, and anaerobic experiments using LB with 40 mM KNO₃ were buffered with 200 mM MOPS (morpholinepropanesulfonic acid) to prevent an increase in culture pH that results from denitrification reactions. Two-hundred-microliter samples were taken over time and used for viable-cell plate counts and to quantify nitrate and chlorate concentrations (described below).

Viable-cell plate counts were performed by serially diluting samples in phosphate-buffered saline (PBS). Dilutions spanning 7 orders of magnitude were plated on LB agar plates as 10-µl drips. Plates were incubated at 37°C for ~20 h, and incubation continued at room temperature (72 h of total incubation) to allow for the growth of slow-growing colonies. Colonies were counted daily, and numbers of CFU per milliliter were calculated at the end of the incubation period. All viable-cell plate counting was carried out under aerobic conditions.

Nitrate and chlorate quantification. Culture samples were centrifuged at 16,000 × *g* at room temperature for 10 min to pellet cells. Supernatants were diluted 1:10 in dH₂O and added to 0.5-ml vials (Thermo Fisher Scientific catalog numbers 038010 and 038011). Nitrate and chlorate concentrations were quantified using the Dionex ICS 2000 ion chromatography system (Environmental Analysis Center, Caltech). Samples were loaded via a 15-µl sample loop onto an AS-19 separator (2- by 250-mm) column protected by an AG-19 guard (2 by 50 mm), maintained at 30°C. A hydroxide gradient was produced using a potassium hydroxide eluent generator cartridge and pumped at 0.25 ml per minute. The gradient began with a 10 mM hold for 10 min, increased linearly to 58 mM at 25 min, and remained at 58 mM until the end of data acquisition at 32 min. Seven minutes was allowed between analyses to return the column to initial conditions. Anions were detected at neutral pH using an AERS 500 2-mm suppressor (Thermo Fisher Scientific) operated in eluent recycle mode with an applied current of 30 mA, and the conductivity detection cell was maintained at 35°C. A carbonate removal device (CRD 200, 2 mm) was installed between the suppressor eluent out port and the conductivity detector eluent in port. Sodium chlorate and potassium nitrate standards were used to identify sample analytes via retention time and to generate standard curves for quantifying analyte concentrations. Similar methods were used to quantify chlorite concentrations, but chlorite was not detected in culture samples (1 µM detection limit).

Construction of *nar* and *nap* complement strains and *narGHJ* mutant strains. To construct complement strains, the *narGHJ* genes were amplified from *P. aeruginosa* using primers 5'-CCATACCC GTTTTTTGGGCTAGCGAATTCGAGCTCAGGAGGAGATCAAGATGAGTCACC-3' and 5'-GCAAATCTGTTTTAT CAGACCGCTTCTCGCTTCTGATTTAAGGTTTCAGGACGACGTTT-3', and the *napEFDABC* genes were amplified using primers 5'- CCATACCCGTTTTTGGGCTAGCGAATTCGAGCTCAGGAGGCTGGGCAATGAACGA AC-3' and 5'- GCAAATCTGTTTTATCAGACCGCTTCTGCGTTCTGATTTAAGCGCTACCGCCCTTACAC-3'. The fragments were each cloned into HindIII-digested pMQ72 (89) downstream of the arabinose-inducible promoter *P*_{ara} via Gibson cloning (NEB number E2611) (90). The resulting plasmids, pMQ72-*narGHJ* and pMQ72-*napEFDABC*, and the empty vector were transformed into *Escherichia coli* DH10B cells. These plasmids and the empty vector were then introduced into *P. aeruginosa* WT and mutant strains via triparental conjugation, and successful exconjugants were selected by plating cells on VBMM medium (91) supplemented with 50 µg ml⁻¹ gentamicin.

The *narGHJ* genes were deleted in WT PA14 and the isogenic Δ *lasR* background. The region upstream of *narG* was amplified using primers 5'-TAAACGACGCGCCAGTGCACGTACTGGGTGTTCCGCC TG-3' and 5'-CGCGCAGGGTCTTGATCTCTCACCCGGTC-3', and the region downstream of *narI* was amplified using primers 5'-GGAGATCAAGACCCCTCGCGCGCCGCGCAT-3' and 5'-CATGATTACGAATTCGA GCTGCTGGCGCGGACGGAAGCGC-3'. These fragments were cloned into HindIII- and SacI-digested pMQ30 (89) via Gibson cloning. The resulting plasmid was transformed into *E. coli* DH10B and introduced into *P. aeruginosa* strains via triparental conjugation, and merodiploids were selected by plating them on VBMM medium (91) supplemented with 50 µg ml⁻¹ gentamicin. Δ *narGHJ* mutants were generated by

resuspending merodiploid cells in PBS and plating them on LB supplemented with 10% sucrose. Correct mutants were confirmed both via PCR and their inability to grow anaerobically with nitrate.

Anaerobic adaptation and survival. Overnight cultures were grown aerobically in LB with 40 mM KNO_3 , 100 mM L-arabinose, 50 $\mu\text{g ml}^{-1}$ gentamicin (for strains containing pMQ72-derived plasmids), and 50 $\mu\text{g ml}^{-1}$ kanamycin (for transposon insertion strains). Overnight cultures were pelleted, washed twice in LB with 100 mM L-arabinose to remove antibiotics, and resuspended in LB with 100 mM L-arabinose with or without 1 mM sodium chlorate at high cell density ($\text{OD}_{500} \sim 3$). Two hundred microliters of resuspended culture was added to 96-well microtiter plates, and the plates were moved to the anaerobic glove box for cells to adapt to the anaerobic lifestyle. After a 72-h incubation at 33°C, 96-well plates were removed from the anaerobic glove box and viable cells on plates were counted to calculate numbers of CFU per milliliter (described above). Percent survival was calculated for each strain by dividing CFU-per-milliliter values from cultures containing chlorate by the average CFU-per-milliliter value from control cultures lacking chlorate and multiplying by 100. CFU-per-milliliter values of untreated control cultures were similar across strains, ranging from 1.0×10^9 to 2.2×10^9 . The percentage of chlorate remaining after the 72-h incubation was determined for each strain by dividing the final chlorate concentration in each culture by the initial chlorate concentration in the medium and multiplying by 100.

ABBA. Overnight aerobic cultures were diluted to an OD_{500} of 0.001 in molten agar growth medium that had been cooled to 44°C. For all agar block biofilm assays (ABBAs), the growth medium used was LB with 5 mM KNO_3 and 0.5% noble agar. A portion of the dilution (175 μl) was added to chambered cover glass slides (Thermo Fisher Scientific number 155409), solidified at room temperature, and incubated at 37°C for 12 h in a humidified chamber. After incubation, cells that were not suspended in the agar were removed by adding 400 μl PBS to the top of each agar block and gently pipetting. Liquid was removed by inversion, and the wash was repeated. Aggregate cells were then treated by pipetting 125 μl of 24 mM sodium chlorate (final concentration, 10 mM), 125 μl 96 $\mu\text{g ml}^{-1}$ tobramycin (final concentration, 40 $\mu\text{g ml}^{-1}$), or 62.5 μl of 48 mM chlorate and 62.5 μl of 192 $\mu\text{g ml}^{-1}$ tobramycin in combination (10 mM and 40- $\mu\text{g-ml}^{-1}$ final concentrations, respectively) on the top of the agar block. All chlorate and tobramycin solutions were made in LB, and 125 μl LB was pipetted on the top of untreated control agar blocks. Treated and untreated samples were incubated at 37°C in a humidified chamber, with shaking at 220 rpm for 6 h. After incubation, samples were inverted to remove liquid, and cells were stained using a BacLight LIVE/DEAD bacterial viability staining kit (Thermo Fisher Scientific number L7012). One hundred twenty-five microliters of staining solution (1 μl 3.34 mM SYTO 9, 1 μl 20 mM propidium iodide, 123 μl dH_2O) was added to each sample, and samples were incubated at room temperature on a VWR variable-speed rocker at the highest speed for 90 min before being imaged.

Confocal microscopy, image analysis, and staining quantification. Before being imaged, ABBA samples were inverted to remove the staining solution, and 75 μl of a 1:50 dilution of 5- μm fluorescent beads (Spherotech; CFP-5045-2) was added to each sample. Excess liquid was removed by wicking, and beads were used to mark the surface of each sample. ABBA aggregates were imaged using a Leica TCS SPE confocal microscope with an ACS APO 0.3-numeric-aperture/10 \times objective. The agar surface was determined by visualizing fluorescent beads using a 405-nm solid-state laser for excitation, with data collected from 425 to 475 nm. LIVE/DEAD data were collected using a 488-nm solid-state laser for excitation, with emission collected at 510 to 550 nm and 610 to 650 nm for SYTO 9 and propidium iodide, respectively. Images were collected from three distinct locations near the center of each well as 500- μm z-stacks (50 slices total, 10- μm step size). z-stacks were collected in 8-bit mode with a scan format of 512 by 512 pixels (for quantification) or 1,024 by 1,024 pixels (for representative images) and line averaging of 2. Representative images were chosen from 6 independent experiments.

To quantify ABBA staining, images were loaded in Fiji (92), and background was subtracted from each image using the rolling ball method with a radius of 100 pixels. A threshold was applied to all images to exclude pixels with a value of <20 , and total pixel intensity for both stains was determined for each image using the RawIntDen value in the Integrated Density measurement function. The proportion of sensitive cells was determined for each image (at each depth) by dividing the propidium iodide integrated density by the sum of the propidium iodide- and SYTO 9-integrated densities. ABBA staining quantifications are averages from 6 independent experiments (3 technical replicates per independent experiment).

Oxygen profiling. Oxygen profiles were determined from treated ABBA samples (12-h growth and 6-h treatment incubations; see above). ABBA samples were kept in a 37°C water bath during oxygen profiling experiments. Oxygen profiles were measured using a Clark-type amperometric electrode with a 25- μm -tip diameter that was connected to a picoampere amplifier in a multimeter (Unisense, Denmark), as described previously (21). Briefly, the microsensor was calibrated using a 37°C oxygen-free solution (0.1 M sodium hydroxide, 0.1 M sodium ascorbate) to obtain a zero-point reading and a 37°C air-saturated, 1% salt solution corresponding to 199.4 μM oxygen. The microsensor was manipulated via a motorized micromanipulator and was positioned 125 to 150 μm above the air-agar interface prior to data collection. The air-agar interface (depth = 0) was defined as the depth at which microsensor values decreased by $>0.5\%$ from its baseline value and was determined by moving the microsensor in 10- μm incremental steps. Profiling data were acquired using SensorTrace Pro 3.1.3 software, with which oxygen was measured at intervals of 25 μm for a total depth of 700 μm . Measuring time at each depth was set at 3 s, with 2 s between measuring points. Oxygen profile data are averages from 3 independent experiments (3 technical replicates per independent experiment).

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <https://doi.org/10.1128/mBio.01400-18>.

FIG S1, PDF file, 0.3 MB.

FIG S2, PDF file, 0.4 MB.

FIG S3, PDF file, 0.6 MB.

FIG S4, PDF file, 0.2 MB.

MOVIE S1, MOV file, 1.5 MB.

MOVIE S2, MOV file, 1.3 MB.

MOVIE S3, MOV file, 1.6 MB.

MOVIE S4, MOV file, 1.3 MB.

ACKNOWLEDGMENTS

This work was supported by grants from the NIH (5R01HL117328-03 and 1R01AI127850-01A1) to D.K.N.

We thank Nathan Dalleska and the Environmental Analysis Center (Caltech) for help with metabolite analyses, William DePas for help developing the ABBA protocol, and Elliot Snow for experimental assistance.

REFERENCES

- Cook GM, Greening C, Hards K, Berney M. 2014. Energetics of pathogenic bacteria and opportunities for drug development. *Advances in microbial physiology*. *Adv Bact Pathog Biol* 65:1–62.
- Vázquez-Torres A, Bäumlér AJ. 2016. Nitrate, nitrite and nitric oxide reductases: from the last universal common ancestor to modern bacterial pathogens. *Curr Opin Microbiol* 29:1–8. <https://doi.org/10.1016/j.mib.2015.09.002>.
- Hassett DJ, Cuppoletti J, Trapnell B, Lyman SV, Rowe JJ, Yoon SS, Hilliard GM, Parvatiyar K, Kamani MC, Wozniak DJ, Hwang SH, McDermott TR, Ochsner UA. 2002. Anaerobic metabolism and quorum sensing by *Pseudomonas aeruginosa* biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets. *Adv Drug Deliv Rev* 54:1425–1443. [https://doi.org/10.1016/S0169-409X\(02\)00152-7](https://doi.org/10.1016/S0169-409X(02)00152-7).
- Lopez CA, Winter SE, Rivera-Chavez F, Xavier MN, Poon V, Nuccio SP, Tsolis RM, Baumler AJ. 2012. Phage-mediated acquisition of a type III secreted effector protein boosts growth of *Salmonella* by nitrate respiration. *mBio* 3:e00143-12. <https://doi.org/10.1128/mBio.00143-12>.
- Winter SE, Winter MG, Xavier MN, Thiennimitr P, Poon V, Keeestra AM, Laughlin RC, Gomez G, Wu J, Lawhon SD, Popova IE, Parikh SJ, Adams LG, Tsolis RM, Stewart VJ, Baumler AJ. 2013. Host-derived nitrate boosts growth of *E. coli* in the inflamed gut. *Science* 339:708–711. <https://doi.org/10.1126/science.1232467>.
- Winter SE, Bäumlér AJ. 2014. Dysbiosis in the inflamed intestine: chance favors the prepared microbe. *Gut Microbes* 5:71–73. <https://doi.org/10.4161/gmic.27129>.
- Fritz C, Maass S, Kreft A, Bange FC. 2002. Dependence of *Mycobacterium bovis* BCG on anaerobic nitrate reductase for persistence is tissue specific. *Infect Immun* 70:286–291. <https://doi.org/10.1128/IAI.70.1.286-291.2002>.
- Jung JY, Madan-Lala R, Georgieva M, Rengarajan J, Sohaskey CD, Bange FC, Robinson CM. 2013. The intracellular environment of human macrophages that produce nitric oxide promotes growth of mycobacteria. *Infect Immun* 81:3198–3209. <https://doi.org/10.1128/IAI.00611-13>.
- Williams MJ, Shanley CA, Zilavy A, Peixoto B, Manca C, Kaplan G, Orme IM, Mizrahi V, Kana BD. 2015. *bis*-Molybdopterin guanine dinucleotide is required for persistence of *Mycobacterium tuberculosis* in guinea pigs. *Infect Immun* 83:544–550. <https://doi.org/10.1128/IAI.02722-14>.
- Abdou E, Deredjian A, de Bagües MPJ, Köhler S, Jubier-Maurin V. 2013. RegA, the regulator of the two-component system RegB/RegA of *Brucella suis*, is a controller of both oxidative respiration and denitrification required for chronic infection in mice. *Infect Immun* 81:2053–2061. <https://doi.org/10.1128/IAI.00063-13>.
- Köhler S, Foulongne V, Ouahrani-Bettache S, Bourg G, Teyssier J, Ramuz M, Liautard JP. 2002. The analysis of the intramacrophagic virulome of *Brucella suis* deciphers the environment encountered by the pathogen inside the macrophage host cell. *Proc Natl Acad Sci U S A* 99:15711–15716. <https://doi.org/10.1073/pnas.232454299>.
- Chin CY, Hara Y, Ghazali AK, Yap SJ, Kong C, Wong YC, Rozali N, Koh SF, Hoh CC, Puthucherry SD, Nathan S. 2015. Global transcriptional analysis of *Burkholderia pseudomallei* high and low biofilm producers reveals insights into biofilm production and virulence. *BMC Genomics* 16:471. <https://doi.org/10.1186/s12864-015-1692-0>.
- Kim HS, Schell MA, Yu Y, Ulrich RL, Sarria SH, Nierman WC, DeShazer D. 2005. Bacterial genome adaptation to niches: divergence of the potential virulence genes in three *Burkholderia* species of different survival strategies. *BMC Genomics* 6:174. <https://doi.org/10.1186/1471-2164-6-174>.
- Yao YF, Sturdevant DE, Otto M. 2005. Genomewide analysis of gene expression in *Staphylococcus epidermidis* biofilms: insights into the pathophysiology of *S. epidermidis* biofilms and the role of phenol-soluble modulins in formation of biofilms. *J Infect Dis* 191:289–298. <https://doi.org/10.1086/426945>.
- Bodey GP, Bolivar R, Fainstein V, Jadeja L. 1983. Infections caused by *Pseudomonas aeruginosa*. *Rev Infect Dis* 5:279–313. <https://doi.org/10.1093/clinids/5.2.279>.
- Chmiel JF, Davis PB. 2003. State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection? *Respir Res* 4:8. <https://doi.org/10.1186/1465-9921-4-8>.
- Howell-Jones RS, Wilson MJ, Hill KE, Howard AJ, Price PE, Thomas DW. 2005. A review of the microbiology, antibiotic usage and resistance in chronic skin wounds. *J Antimicrob Chemother* 55:143–149. <https://doi.org/10.1093/jac/dkh513>.
- Ramirez-Estrada S, Borgatta B, Rello J. 2016. *Pseudomonas aeruginosa* ventilator-associated pneumonia management. *Infect Drug Resist* 9:7–18. <https://doi.org/10.2147/IDR.S50669>.
- Palmer KL, Aye LM, Whiteley M. 2007. Nutritional cues control *Pseudomonas aeruginosa* multicellular behavior in cystic fibrosis sputum. *J Bacteriol* 189:8079–8087. <https://doi.org/10.1128/JB.01138-07>.
- Line L, Alhede M, Kolpen M, Kühl M, Ciofu O, Bjarnsholt T, Moser C, Toyofuku M, Nomura N, Høiby N, Jensen PØ. 2014. Physiological levels of nitrate support anoxic growth by denitrification of *Pseudomonas aeruginosa* at growth rates reported in cystic fibrosis lungs and sputum. *Front Microbiol* 5:554. <https://doi.org/10.3389/fmicb.2014.00554>.
- Cowley ES, Kopf SH, LaRiviere A, Ziebis W, Newman DK. 2015. Pediatric cystic fibrosis sputum can be chemically dynamic, anoxic, and extremely reduced due to hydrogen sulfide formation. *mBio* 6:e00767-15. <https://doi.org/10.1128/mBio.00767-15>.
- James GA, Ge Zhao A, Usui M, Underwood RA, Nguyen H, Beyenal H, deLancey Pulcini E, Agostinho Hunt A, Bernstein HC, Fleckman P, Olerud J, Williamson KS, Franklin MJ, Stewart PS. 2016. Microsensor and transcriptomic signatures of oxygen depletion in biofilms associated with

- chronic wounds. *Wound Repair Regen* 24:373–383. <https://doi.org/10.1111/wrr.12401>.
23. Bernatchez SF, Menon V, Stoffel J, Walters SA, Lindroos WE, Crossland MC, Shawler LG, Crossland SP, Boykin JV, Jr. 2013. Nitric oxide levels in wound fluid may reflect the healing trajectory. *Wound Repair Regen* 21:410–417. <https://doi.org/10.1111/wrr.12048>.
 24. Richardson DJ, Berks BC, Russell DA, Spiro S, Taylor CJ. 2001. Functional, biochemical and genetic diversity of prokaryotic nitrate reductases. *Cell Mol Life Sci* 58:165–178. <https://doi.org/10.1007/PL00000845>.
 25. Palmer KL, Brown SA, Whiteley M. 2007. Membrane-bound nitrate reductase is required for anaerobic growth in cystic fibrosis sputum. *J Bacteriol* 189:4449–4455. <https://doi.org/10.1128/JB.00162-07>.
 26. Son MS, Matthews WJ, Kang Y, Nguyen DT, Hoang TT. 2007. In vivo evidence of *Pseudomonas aeruginosa* nutrient acquisition and pathogenesis in the lungs of cystic fibrosis patients. *Infect Immun* 75:5313–5324. <https://doi.org/10.1128/IAI.01807-06>.
 27. Quinn RA, Lim YW, Maughan H, Conrad D, Rohwer F, Whiteson KL. 2014. Biogeochemical forces shape the composition and physiology of polymicrobial communities in the cystic fibrosis lung. *mBio* 5:e00956-13. <https://doi.org/10.1128/mBio.00956-13>.
 28. Kolpen M, Kühl M, Bjarnsholt T, Moser C, Hansen CR, Liengaard L, Kharazmi A, Pressler T, Høiby N, Jensen PØ. 2014. Nitrous oxide production in sputum from cystic fibrosis patients with chronic *Pseudomonas aeruginosa* lung infection. *PLoS One* 9:e84353. <https://doi.org/10.1371/journal.pone.0084353>.
 29. Beckmann C, Brittnacher M, Ernst R, Mayer-Hamblett N, Miller SI, Burns JL. 2005. Use of phage display to identify potential *Pseudomonas aeruginosa* gene products relevant to early cystic fibrosis airway infections. *Infect Immun* 73:444–452. <https://doi.org/10.1128/IAI.73.1.444-452.2005>.
 30. Kopf SH, Sessions AL, Cowley ES, Reyes C, Van Sambeek L, Hu Y, Orphan VJ, Kato R, Newman DK. 2016. Trace incorporation of heavy water reveals slow and heterogeneous pathogen growth rates in cystic fibrosis sputum. *Proc Natl Acad Sci U S A* 113:E110–E116. <https://doi.org/10.1073/pnas.1512057112>.
 31. Alvarez-Ortega C, Harwood CS. 2007. Responses of *Pseudomonas aeruginosa* to low oxygen indicate that growth in the cystic fibrosis lung is by aerobic respiration. *Mol Microbiol* 65:153–165. <https://doi.org/10.1111/j.1365-2958.2007.05772.x>.
 32. Borriello G, Werner E, Roe F, Kim AM, Ehrlich GD, Stewart PS. 2004. Oxygen limitation contributes to antibiotic tolerance of *Pseudomonas aeruginosa* in biofilms. *Antimicrob Agents Chemother* 48:2659–2664. <https://doi.org/10.1128/AAC.48.7.2659-2664.2004>.
 33. Evans DJ, Allison DG, Brown MR, Gilbert P. 1991. Susceptibility of *Pseudomonas aeruginosa* and *Escherichia coli* biofilms towards ciprofloxacin: effect of specific growth rate. *J Antimicrob Chemother* 27:177–184. <https://doi.org/10.1093/jac/27.2.177>.
 34. Coates A, Hu Y, Bax R, Page C. 2002. The future challenges facing the development of new antimicrobial drugs. *Nat Rev Drug Discov* 1:895–910. <https://doi.org/10.1038/nrd940>.
 35. Leviton IM, Fraimow HS, Carrasco N, Dougherty TJ, Miller MH. 1995. Tobramycin uptake in *Escherichia coli* membrane vesicles. *Antimicrob Agents Chemother* 39:467–475. <https://doi.org/10.1128/AAC.39.2.467>.
 36. Mates SM, Patel L, Kaback HR, Miller MH. 1983. Membrane potential in anaerobically growing *Staphylococcus aureus* and its relationship to gentamicin uptake. *Antimicrob Agents Chemother* 23:526–530. <https://doi.org/10.1128/AAC.23.4.526>.
 37. Allison KR, Brynildsen MP, Collins JJ. 2011. Metabolite-enabled eradication of bacterial persisters by aminoglycosides. *Nature* 473:216–220. <https://doi.org/10.1038/nature10069>.
 38. Fux CA, Costerton JW, Stewart PS, Stoodley P. 2005. Survival strategies of infectious biofilms. *Trends Microbiol* 13:34–40. <https://doi.org/10.1016/j.tim.2004.11.010>.
 39. DePas WH, Starwalt-Lee R, Van Sambeek L, Ravindra Kumar S, Gradinaru V, Newman DK. 2016. Exposing the three-dimensional biogeography and metabolic states of pathogens in cystic fibrosis sputum via hydrogel embedding, clearing, and rRNA labeling. *mBio* 7:e00796-16. <https://doi.org/10.1128/mBio.00796-16>.
 40. Bjarnsholt T, Alhede M, Alhede M, Eickhardt-Sørensen SR, Moser C, Kühl M, Jensen PØ, Høiby N. 2013. The *in vivo* biofilm. *Trends Microbiol* 21:466–474. <https://doi.org/10.1016/j.tim.2013.06.002>.
 41. Pamp SJ, Gjermansen M, Johansen HK, Tolker-Nielsen T. 2008. Tolerance to the antimicrobial peptide colistin in *Pseudomonas aeruginosa* biofilms is linked to metabolically active cells, and depends on the *pmr* and *mexAB-oprM* genes. *Mol Microbiol* 68:223–240. <https://doi.org/10.1111/j.1365-2958.2008.06152.x>.
 42. Williamson KS, Richards LA, Perez-Osorio AC, Pitts B, McInerney K, Stewart PS, Franklin MJ. 2012. Heterogeneity in *Pseudomonas aeruginosa* biofilms includes expression of ribosome hibernation factors in the antibiotic-tolerant subpopulation and hypoxia-induced stress response in the metabolically active population. *J Bacteriol* 194:2062–2073. <https://doi.org/10.1128/JB.00222-12>.
 43. Walters MC, III, Roe F, Bugnicourt A, Franklin MJ, Stewart PS. 2003. Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of *Pseudomonas aeruginosa* biofilms to ciprofloxacin and tobramycin. *Antimicrob Agents Chemother* 47:317–323. <https://doi.org/10.1128/AAC.47.1.317-323.2003>.
 44. Meylan S, Porter CBM, Yang JH, Belenky P, Gutierrez A, Lobritz MA, Park J, Kim SH, Moskowitz SM, Collins JJ. 2017. Carbon sources tune antibiotic susceptibility in *Pseudomonas aeruginosa* via tricarboxylic acid cycle control. *Cell Chem Biol* 24:195–206. <https://doi.org/10.1016/j.chembiol.2016.12.015>.
 45. Koeva M, Gutu AD, Heber W, Wager JD, Yonker LM, O'Toole GA, Ausubel FM, Moskowitz SM, Joseph-McCarthy D. 2017. An antipersister strategy for treatment of chronic *Pseudomonas aeruginosa* infections. *Antimicrob Agents Chemother* 61. <https://doi.org/10.1128/AAC.00987-17>.
 46. Hoffman LR, Kulasekara HD, Emerson J, Houston LS, Burns JL, Ramsey BW, Miller SI. 2009. *Pseudomonas aeruginosa lasR* mutants are associated with cystic fibrosis lung disease progression. *J Cyst Fibros* 8:66–70. <https://doi.org/10.1016/j.jcf.2008.09.006>.
 47. Köhler T, Buckling A, van Delden C. 2009. Cooperation and virulence of clinical *Pseudomonas aeruginosa* populations. *Proc Natl Acad Sci U S A* 106:6339–6344. <https://doi.org/10.1073/pnas.0811741106>.
 48. Hamood AN, Griswold J, Colmer J. 1996. Characterization of elastase-deficient clinical isolates of *Pseudomonas aeruginosa*. *Infect Immun* 64:3154–3160.
 49. Smith EE, Buckley DG, Wu ZN, Saenphimmachak C, Hoffman LR, D'Argenio DA, Miller SI, Ramsey BW, Speert DP, Moskowitz SM, Burns JL, Kaul R, Olson MV. 2006. Genetic adaptation by *Pseudomonas aeruginosa* to the airways of cystic fibrosis patients. *Proc Natl Acad Sci U S A* 103:8487–8492. <https://doi.org/10.1073/pnas.0602138103>.
 50. Cabrol S, Olliver A, Pier GB, Andremont A, Ruimy R. 2003. Transcription of quorum-sensing system genes in clinical and environmental isolates of *Pseudomonas aeruginosa*. *J Bacteriol* 185:7222–7230. <https://doi.org/10.1128/JB.185.24.7222-7230.2003>.
 51. Hoffman LR, Richardson AR, Houston LS, Kulasekara HD, Martens-Habbena W, Klausen M, Burns JL, Stahl DA, Hassett DJ, Fang FC, Miller SI. 2010. Nutrient availability as a mechanism for selection of antibiotic tolerant *Pseudomonas aeruginosa* within the CF airway. *PLoS Pathog* 6:e1000712. <https://doi.org/10.1371/journal.ppat.1000712>.
 52. D'Argenio DA, Wu M, Hoffman LR, Kulasekara HD, Déziel E, Smith EE, Nguyen H, Ernst RK, Larson Freeman TJ, Spencer DH, Brittnacher M, Hayden HS, Selgrade S, Klausen M, Goodlett DR, Burns JL, Ramsey BW, Miller SI. 2007. Growth phenotypes of *Pseudomonas aeruginosa lasR* mutants adapted to the airways of cystic fibrosis patients. *Mol Microbiol* 64:512–533. <https://doi.org/10.1111/j.1365-2958.2007.05678.x>.
 53. Hochstein LI, Tomlinson GA. 1988. The enzymes associated with denitrification. *Annu Rev Microbiol* 42:231–261. <https://doi.org/10.1146/annurev.mi.42.100188.001311>.
 54. Puig J, Azoulay E, Pichinoty F, Gendre J. 1969. Genetic mapping of the *chl C* gene of the nitrate reductase system in *Escherichia coli* K₁₂. *Biochem Biophys Res Commun* 35:659–662. [https://doi.org/10.1016/0006-291X\(69\)90455-0](https://doi.org/10.1016/0006-291X(69)90455-0).
 55. Health Canada. 2008. Guidelines for Canadian drinking water quality: guideline technical document—chlorite and chlorate. Health Canada, Ottawa, ON. <https://www.canada.ca/content/dam/canada/health-canada/migration/healthy-canadians/publications/healthy-living-vie-saine/eau/chlorite-chlorate-eau/alt/water-chlorite-chlorate-eau-eng.pdf>.
 56. van Wijk DJ, Kroon SG, Gattener-Arends IC. 1998. Toxicity of chlorate and chlorite to selected species of algae, bacteria, and fungi. *Ecotoxicol Environ Saf* 40:206–211. <https://doi.org/10.1006/eesa.1998.1685>.
 57. Smith DJ, Oliver CE, Taylor JB, Anderson RC. 2012. Invited review: efficacy, metabolism, and toxic responses to chlorate salts in food and laboratory animals. *J Anim Sci* 90:4098–4117. <https://doi.org/10.2527/jas.2011-4997>.
 58. Cha CN, Jung WC, Choi H, Lee YE, Yoo CY, Kim S, Lee HJ. 2012. Effects of short-term sodium chlorate exposure on pigs. *Acta Vet Hung* 60:93–101. <https://doi.org/10.1556/AVet.2012.008>.

59. Taylor JB, Smith DJ. 2015. Continuous, low-dose oral exposure to sodium chlorate reduces fecal generic in sheep feces without inducing clinical chlorate toxicosis. *J Anim Sci* 93:1942–1951. <https://doi.org/10.2527/jas.2014-8568>.
60. Jackson RC, Elder WJ, McDonnell H. 1961. Sodium-chlorate poisoning complicated by acute renal failure. *Lancet* ii:1381–1383.
61. Helliwell M, Nunn J. 1979. Mortality in sodium chlorate poisoning. *Br Med J* 1:1119. <https://doi.org/10.1136/bmj.1.6171.1119>.
62. Darkwa J, Olojo R, Chikwana E, Simoyi RH. 2004. Antioxidant chemistry: oxidation of L-cysteine and its metabolites by chlorite and chlorine dioxide. *J Phys Chem A* 108:5576–5587. <https://doi.org/10.1021/jp049748k>.
63. Pattison DI, Davies MJ. 2001. Absolute rate constants for the reaction of hypochlorous acid with protein side chains and peptide bonds. *Chem Res Toxicol* 14:1453–1464. <https://doi.org/10.1021/tx0155451>.
64. Winter J, Ilbert M, Graf PC, Özcelik D, Jakob U. 2008. Bleach activates a redox-regulated chaperone by oxidative protein unfolding. *Cell* 135:691–701. <https://doi.org/10.1016/j.cell.2008.09.024>.
65. Basta DW, Bergkessel M, Newman DK. 2017. Identification of fitness determinants during energy-limited growth arrest in *Pseudomonas aeruginosa*. *mBio* 8:e01170-17. <https://doi.org/10.1128/mBio.01170-17>.
66. Groitl B, Dahl JU, Schroeder JW, Jakob U. 2017. *Pseudomonas aeruginosa* defense systems against microbicidal oxidants. *Mol Microbiol* 106:335–350. <https://doi.org/10.1111/mmi.13768>.
67. Costa KC, Glasser NR, Conway SJ, Newman DK. 2017. Pyocyanin degradation by a tautomerizing demethylase inhibits *Pseudomonas aeruginosa* biofilms. *Science* 355:170–173. <https://doi.org/10.1126/science.aag3180>.
68. Sønderholm M, Koren K, Wangpraseurt D, Jensen PØ, Kolpen M, Kragh KN, Bjarnsholt T, Kühl M. 2018. Tools for studying growth patterns and chemical dynamics of aggregated *Pseudomonas aeruginosa* exposed to different electron acceptors in an alginate bead model. *NPJ Biofilms Microbiomes* 4:3. <https://doi.org/10.1038/s41522-018-0047-4>.
69. Stewart PS, Franklin MJ. 2008. Physiological heterogeneity in biofilms. *Nat Rev Microbiol* 6:199–210. <https://doi.org/10.1038/nrmicro1838>.
70. Stocks SM. 2004. Mechanism and use of the commercially available viability stain, BacLight. *Cytometry A* 61:189–195. <https://doi.org/10.1002/cyto.a.20069>.
71. Teal TK, Lies DP, Wold BJ, Newman DK. 2006. Spatiometabolic stratification of *Shewanella oneidensis* biofilms. *Appl Environ Microbiol* 72:7324–7330. <https://doi.org/10.1128/AEM.01163-06>.
72. MacGregor CH. 1975. Synthesis of nitrate reductase components in chlorate-resistant mutants of *Escherichia coli*. *J Bacteriol* 121:1117–1121.
73. Stouthamer AH. 1967. Nitrate reduction in *Aerobacter aerogenes*. I. Isolation and properties of mutant strains blocked in nitrate assimilation and resistant against chlorate. *Arch Mikrobiol* 56:68–75. <https://doi.org/10.1007/BF00406055>.
74. Van Hartingsveldt J, Marinus MG, Stouthamer AH. 1971. Mutants of *Pseudomonas aeruginosa* blocked in nitrate or nitrite dissimilation. *Genetics* 67:469–482.
75. Trämper-Stranders GA, van der Ent CK, Molin S, Yang L, Hansen SK, Rau MH, Ciofu O, Johansen HK, Wolfs TF. 2012. Initial *Pseudomonas aeruginosa* infection in patients with cystic fibrosis: characteristics of eradicated and persistent isolates. *Clin Microbiol Infect* 18:567–574. <https://doi.org/10.1111/j.1469-0691.2011.03627.x>.
76. Hurdle JG, O'Neill AJ, Chopra I, Lee RE. 2011. Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. *Nat Rev Microbiol* 9:62–75. <https://doi.org/10.1038/nrmicro2474>.
77. Meylan S, Andrews IW, Collins JJ. 2018. Targeting antibiotic tolerance, pathogen by pathogen. *Cell* 172:1228–1238. <https://doi.org/10.1016/j.cell.2018.01.037>.
78. Conlon BP, Nakayasu ES, Fleck LE, LaFleur MD, Isabella VM, Coleman K, Leonard SN, Smith RD, Adkins JN, Lewis K. 2013. Activated ClpP kills persisters and eradicates a chronic biofilm infection. *Nature* 503:365–370. <https://doi.org/10.1038/nature12790>.
79. Mogayzel PJ, Jr, Naureckas ET, Robinson KA, Mueller G, Hadjilias D, Hoag JB, Lubsch L, Hazle L, Sabadosa K, Marshall B, Pulmonary Clinical Practice Guidelines Committee. 2013. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. *Am J Respir Crit Care Med* 187:680–689. <https://doi.org/10.1164/rccm.201207-1160OE>.
80. Imamura Y, Higashiyama Y, Tomono K, Izumikawa K, Yanagihara K, Ohno H, Miyazaki Y, Hirakata Y, Mizuta Y, Kadota J, Iglewski BH, Kohno S. 2005. Azithromycin exhibits bactericidal effects on *Pseudomonas aeruginosa* through interaction with the outer membrane. *Antimicrob Agents Chemother* 49:1377–1380. <https://doi.org/10.1128/AAC.49.4.1377-1380.2005>.
81. Renna M, Schaffner C, Brown K, Shang S, Tamayo MH, Hegyi K, Grimsey NJ, Cusens D, Coulter S, Cooper J, Bowden AR, Newton SM, Kampmann B, Helm J, Jones A, Haworth CS, Basaraba RJ, DeGroot MA, Ordway DJ, Rubinsztein DC, Floto RA. 2011. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. *J Clin Invest* 121:3554–3563. <https://doi.org/10.1172/JCI46095>.
82. Fuchs S, Pané-Farré J, Kohler C, Hecker M, Engelmann S. 2007. Anaerobic gene expression in *Staphylococcus aureus*. *J Bacteriol* 189:4275–4289. <https://doi.org/10.1128/JB.00081-07>.
83. Li SF, DeMoss JA. 1987. Promoter region of the nar operon of *Escherichia coli*: nucleotide sequence and transcription initiation signals. *J Bacteriol* 169:4614–4620. <https://doi.org/10.1128/jb.169.10.4614-4620.1987>.
84. Murima P, McKinney JD, Pethe K. 2014. Targeting bacterial central metabolism for drug development. *Chem Biol* 21:1423–1432. <https://doi.org/10.1016/j.chembiol.2014.08.020>.
85. Eschbach M, Schreiber K, Trunk K, Buer J, Jahn D, Schobert M. 2004. Long-term anaerobic survival of the opportunistic pathogen *Pseudomonas aeruginosa* via pyruvate fermentation. *J Bacteriol* 186:4596–4604. <https://doi.org/10.1128/JB.186.14.4596-4604.2004>.
86. Glasser NR, Kern SE, Newman DK. 2014. Phenazine redox cycling enhances anaerobic survival in *Pseudomonas aeruginosa* by facilitating generation of ATP and a proton-motive force. *Mol Microbiol* 92:399–412. <https://doi.org/10.1111/mmi.12566>.
87. Banin E, Lozinski A, Brady KM, Berenshtein E, Butterfield PW, Moshe M, Chevion M, Greenberg EP, Banin E. 2008. The potential of desferrioxamine-gallium as an anti-*Pseudomonas* therapeutic agent. *Proc Natl Acad Sci U S A* 105:16761–16766. <https://doi.org/10.1073/pnas.0808608105>.
88. Miller MJ, Walz AJ, Zhu H, Wu C, Moraski G, Mollmann U, Tristani EM, Crumbliss AL, Ferdig MT, Checkley L, Edwards RL, Boshoff HI. 2011. Design, synthesis, and study of a mycobactin-artemisinin conjugate that has selective and potent activity against tuberculosis and malaria. *J Am Chem Soc* 133:2076–2079. <https://doi.org/10.1021/ja109665t>.
89. Shanks RM, Caiazza NC, Hinsa SM, Toutain CM, O'Toole GA. 2006. *Saccharomyces cerevisiae*-based molecular tool kit for manipulation of genes from Gram-negative bacteria. *Appl Environ Microbiol* 72:5027–5036. <https://doi.org/10.1128/AEM.00682-06>.
90. Gibson DG. 2011. Enzymatic assembly of overlapping DNA fragments. *Methods Enzymol* 498:349–361. <https://doi.org/10.1016/B978-0-12-385120-8.00015-2>.
91. Choi KH, Schweizer HP. 2006. mini-Tn7 insertion in bacteria with single attTn7 sites: example *Pseudomonas aeruginosa*. *Nat Protoc* 1:153–161. <https://doi.org/10.1038/nprot.2006.24>.
92. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A. 2012. Fiji: an open-source platform for biological-image analysis. *Nat Methods* 9:676–682. <https://doi.org/10.1038/nmeth.2019>.